Program
cannabis sativa flowering TOP
Also written as “Cannabis oil”, “MGCND00EP1” and “Medical Grade Cannabis oil”.
Its studies are mostly in Drug Resistant Epilepsy · Attention Deficit Disorder with Hyperactivity · Autistic Disorder · Hidradenitis Suppurativa, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TO Pharmaceuticals | 20 open or running | phase 2since Apr 24, 2019 | Apr 24, 2019 | none ahead |
| Brlev Agricultural Crops | 10 open or running | phase 2since Dec 30, 2021 | Dec 30, 2021 | none ahead |
| GreenCare Pharma | 11 open or running | phase 1since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| MGC Pharmaceuticals d.o.o | 10 open or running | phase 2since May 17, 2020 | May 17, 2020 | none ahead |
| New Age Ventures | 10 open or running | phase 1since Jul 29, 2020 | Jul 29, 2020 | none ahead |
Also a collaborator on its studies: Bio-Sciences Pharma and KGK Science.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2019First studies: 2 phase 2 studiesNew to TO PharmaceuticalsTO Pharmaceuticals · NCT05413187, NCT03929835
- May 17, 2020MGC Pharmaceuticals d.o.o’s first study: phase 2 study in Drug Resistant EpilepsyNew to MGC Pharmaceuticals d.o.oMGC Pharmaceuticals d.o.o · NCT04406948 · Israel, Slovenia
- Jul 29, 2020New Age Ventures’ first study: phase 1 study in Marijuana AbuseNew to New Age VenturesNew Age Ventures · NCT04601207 · 32 enrolled · Canada
- Dec 30, 2021Brlev Agricultural Crops’ first study: phase 2 study in Attention Deficit Disorder with HyperactivityNew to Brlev Agricultural CropsBrlev Agricultural Crops · NCT05219370 · 8 enrolled · Israel
- Jan 17, 2025GreenCare Pharma’s first study: phase 1 study in HealthyNew to GreenCare PharmaGreenCare Pharma · NCT06807762 · 72 planned · Brazil
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06807762Healthy · Brazil | 1 | Recruiting | GreenCare Pharma | Jun 2025 | 72 |
| NCT05219370Attention Deficit Disorder with Hyperactivity · Israel | 2 | Terminated | Brlev Agricultural Crops | Dec 31, 2022 | 8 |
| NCT04601207Marijuana Abuse · Canada | 1 | Completed | New Age Ventures | Nov 30, 2020 | 32 |
| NCT04406948Drug Resistant Epilepsy · Israel, Slovenia | 2 | Withdrawn | MGC Pharmaceuticals d.o.o | May 30, 2024 | 0 |
| NCT05413187Autistic Disorder · Israel | 2 | Withdrawn | TO Pharmaceuticals | Sep 1, 2022 | 0 |
| NCT03929835Hidradenitis Suppurativa · Israel | 2 | Withdrawn | TO Pharmaceuticals | Sep 1, 2022 | 0 |
How it is read
Names in the registry
- “Cannabis oil”, 3 entries
- “MGCND00EP1”, 1 entry
- “Medical Grade Cannabis oil”, 1 entry
- “Cannabis Preparation”, 1 entry
Conditions, from the studies’ own filings
- Drug Resistant Epilepsy, 1 study
- Attention Deficit Disorder with Hyperactivity, 1 study
- Autistic Disorder, 1 study
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.